SAM
KPTI icon

Silverback Asset Management’s Karyopharm Therapeutics KPTI Stock Holding History

Silverback Asset Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$557K Buy
+100,000
New +$762K 0.08% 56

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Silverback Asset Management's KPTI Position: Q1 2026 in Review

Silverback Asset Management increased its Karyopharm Therapeutics (KPTI) stake by 63% in Q1 2026, buying an estimated $191K and bringing the position to 65,000 shares worth $362K. The position accounts for 0.05% of the portfolio, ranked #57.

Silverback Asset Management first reported a position in KPTI in Q2 2025 and has held it in 4 quarters since. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • Silverback Asset Management held 65,000 shares of Karyopharm Therapeutics worth $362K as of Q1 2026.
  • Silverback Asset Management bought 25,000 Karyopharm Therapeutics shares in Q1 2026, an estimated $191K.
  • Karyopharm Therapeutics made up 0.05% of Silverback Asset Management's portfolio in Q1 2026, its #57 holding.
  • Silverback Asset Management first reported a position in Karyopharm Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Silverback Asset Management's 13F filing for Q1 2026, filed 14 May 2026.